A clinical and scientific overview of tositumomab and iodine I 131 tositumomab

Seminars in Oncology

Volumn 30, Issue 2 SUPPL. 4, 2003, Pages 22-30

  Zelenetz, Andrew D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIBODY; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ANOREXIA; ARTHRALGIA; ASTHENIA; B LYMPHOCYTE; BLOOD TOXICITY; CANCER GRADING; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL TRIAL; DISEASE SEVERITY; DOSIMETRY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEVER; HUMAN; INCIDENCE; INFECTION; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHODGKIN LYMPHOMA; PAIN; PRIORITY JOURNAL; PRURITUS; RADIOIMMUNOTHERAPY; RASH; REVIEW; TREATMENT OUTCOME;

EID: 0037397622     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(03)70054-2     Document Type: Review

References (31)

1. Press OW, Appelbaum F, Ledbetter JA, et al: Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69:584-591, 1987
2. Hekman A, Honselaar A, Vuist WM, et al: Initial experience with treatment of human B cell lymphoma with antiCD19 monoclonal antibody. Cancer Immunol Immunother 32:364-372, 1991
3. Juweid M, Sharkey RM, Markowitz A, et al: Treatment of non-Hodgkin's lymphoma with radiolabeled murine chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 55:5899S-5907S, 1995 (suppl 23)
4. Dyer MJ, Hale G, Hayhoe FG, et al: Effects of CAMPATH-I antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype. Blood 73:1431-1439, 1989
5. Hu E, Epstein AL, Naeve GS, et al: A phase Ia clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies. Hematol Oncol 7:155-166, 1989
6. Link BK, Wang H, Byrd JC, et al: Phase I trial of humanized 1D10 (Hu1D10) monoclonal antibody targeting class II molecules in patients with relapsed lymphoma. Proc Am Soc Clin Oncol 19:24a, 2000 (abstr)
7. Shan D, Ledbetter JA, Press OW: Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91:1644-1652, 1998
8. Buchsbaum DJ, Wahl RL, Normolle DP, et al: Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res 52:6476-6481, 1992
9. Flieger D, Renoth S, Beier 1, et al: Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody lDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol 204:55-63, 2000
10. Golay J, Zaffaroni L, Vaccari T, et al: Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95:3900-3908, 2000
11. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
12. Czuczman MS, Grillo-Lopez AJ, White CA, et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999
13. Kaminski MS, Estes J, Zasadny KR, et al: Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and longterm follow-up of the University of Michigan experience. Blood 96:1259-1266, 2000
14. Vose JM, Wahl RL, Saleh M, et al: Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 18:1316-1323, 2000
15. Kaminski MS, Zelenetz AD, Press O, et al: Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory lowgrade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19:3918-3928, 2001
16. Zelenetz AD, Vose JM, Knox S, et al: Iodine I 131 tositumomab for patients with transformed low-grade non-Hodgkin's lymphoma (NHL): Overall clinical trial experience. Blood 94:632a, 1999 (suppl 1 pt 1) (abstr)
17. Vose JM, Zelenetz AD, Rohatiner A, et al: Iodine I 131 tositumomab for patients with follicular non-Hodgkin's lymphoma (NHL): Overall clinical trial experience by histology. Blood 94:89a, 1999 (suppl 1) (abstr 387)
18. Leonard JP, Frenette G, Dillman RO, et al: Interim safety and efficacy results of Bexxar in a large multicenter expanded access study. Blood 98:133a, 2001 (suppl) (abstr 599)
19. Leonard JP, Zelenetz AD, Vose JM, et al: Bexxar (tositumomab and iodine I 131 tositumomab) results in durable long-term responses in patients with poor prognosis, multiple relapsed (rel), and refractory (ref) low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL). Blood 98:603a, 2001 (suppl) (abstr 2527)
20. Ersboll J, Schultz HB, Pedersen-Bjergaard J, et al: Follicular low-grade non-Hodgkin's lymphoma: Long-term outcome with or without tumor progression. Eur J Haematol 42: 155-163, 1989
21. Kamiski MS, Kaur TL, Zelenetz AD, et al: Treatment of transformed and refractory low-grade lymphoma with Bexxar therapy is associated with improvements in quality of life. Blood 98:427a, 2001 (suppl) (abstr 1790)
22. Armitage JO, Weisenburger DD: New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 16:2780-2795, 1998
23. Knox SJ, Goris ML, Davis TA, et al: Randomized controlled study of iodine-131 anti-B1 antibody vs unlabeledanti-B1 antibody in patients with chemotherapy refractory low-grade non-Hodgkin's lymphoma. Poster presentation at the 39th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), Orlando, FL, October 19-23, 1997
24. Kaminski MS, Gribbin T, Estes J, et al: I-131 anti-B1 antibody for previously untreated follicular lymphoma (FL): Clinical and molecular remissions. Proc Am Soc Clin Oncol 17:2a, 1998 (abstr 6)
25. Investigator's Brochure: Bexxar. Corixa Corporation, San Francisco, CA, 1999
26. Kaminski MS, Gregory SA, Fehrenbacher L, et al: Acute and delayed hematologic toxicities associated with Bexxar therapy are modest: Overall experience in patients with lowgrade and transformed low-grade NHL. Blood 98:339a, 2001 (suppl) (abstr 1433)
27. Gregory SA, Coleman M, Dillman RO, et al: Bexxar is a well-tolerated therapy in elderly patients with low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL). Blood 98:605a, 2001 (suppl) (abstr 2535)
28. Bennett JM, Zelenetz AD, Press OW, et al: Incidence of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in patients with low-grade non-Hodgkin's lymphoma (LG-NHL) treated with Bexxar. Blood 98:335a, 2001 (suppl) (abstr 1416)
29. Valente N: Oral abstract presented at the 7th International Conference on Malignant Lymphoma. Lugano, Switzerland, June 2-5, 1999
30. Valente NK, Kaminiski MS, Knox SJ, et al: Subsequent therapy can be administered following treatment with iodine131 anti-B1 antibody in patients with non-Hodgkin's lymphoma (NHL). Ann Oncol 10:33, 1999 (abstr)
31. Kaminski MS, Bahm V, Estes J, et al: Tolerance of treatment subsequent to frontline Bexxar (tositumomab and iodine I 131 tositumomab) in patients (Pts) with follicular lymphoma. Blood 98:603a, 2001 (suppl) (abstr 2526)